These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 2405783)

  • 1. Fenfluramine in Prader-Willi syndrome: a double blind, placebo controlled trial.
    Selikowitz M; Sunman J; Pendergast A; Wright S
    Arch Dis Child; 1990 Jan; 65(1):112-4. PubMed ID: 2405783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promising effects of oxytocin on social and food-related behaviour in young children with Prader-Willi syndrome: a randomized, double-blind, controlled crossover trial.
    Kuppens RJ; Donze SH; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2016 Dec; 85(6):979-987. PubMed ID: 27486141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial.
    Allas S; Caixàs A; Poitou C; Coupaye M; Thuilleaux D; Lorenzini F; Diene G; Crinò A; Illouz F; Grugni G; Potvin D; Bocchini S; Delale T; Abribat T; Tauber M
    PLoS One; 2018; 13(1):e0190849. PubMed ID: 29320575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of topiramate on eating behaviours in Prader-Willi syndrome: TOPRADER double-blind randomised placebo-controlled study.
    Consoli A; Çabal Berthoumieu S; Raffin M; Thuilleaux D; Poitou C; Coupaye M; Pinto G; Lebbah S; Zahr N; Tauber M; Cohen D; Bonnot O
    Transl Psychiatry; 2019 Nov; 9(1):274. PubMed ID: 31685813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The probable anorexigenic effect of naloxone in the Prader-Labhart-Willi syndrome].
    Mascherpa G; Cogliati F; Mauri R; Resentini M
    Minerva Pediatr; 1982 Aug 15-31; 34(15-16):675. PubMed ID: 7121431
    [No Abstract]   [Full Text] [Related]  

  • 6. Growth hormone treatment improves vitality and behavioural issues in children with Prader-Willi syndrome.
    Böhm B; Ritzén EM; Lindgren AC
    Acta Paediatr; 2015 Jan; 104(1):59-67. PubMed ID: 25263744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A controlled crossover trial of fenfluramine in autism.
    Stern LM; Walker MK; Sawyer MG; Oades RD; Badcock NR; Spence JG
    J Child Psychol Psychiatry; 1990 May; 31(4):569-85. PubMed ID: 2195054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychotropic treatments in Prader-Willi syndrome: a critical review of published literature.
    Bonnot O; Cohen D; Thuilleaux D; Consoli A; Cabal S; Tauber M
    Eur J Pediatr; 2016 Jan; 175(1):9-18. PubMed ID: 26584571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of Bifidobacterium animalis ssp. lactis B94 on gastrointestinal wellness in adults with Prader-Willi syndrome: study protocol for a randomized controlled trial.
    Alyousif Z; Miller JL; Sandoval MY; MacPherson CW; Nagulesapillai V; Dahl WJ
    Trials; 2018 Apr; 19(1):256. PubMed ID: 29703235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-acting octreotide treatment causes a sustained decrease in ghrelin concentrations but does not affect weight, behaviour and appetite in subjects with Prader-Willi syndrome.
    De Waele K; Ishkanian SL; Bogarin R; Miranda CA; Ghatei MA; Bloom SR; Pacaud D; Chanoine JP
    Eur J Endocrinol; 2008 Oct; 159(4):381-8. PubMed ID: 18603572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind randomized controlled trial of oxytocin nasal spray in Prader Willi syndrome.
    Einfeld SL; Smith E; McGregor IS; Steinbeck K; Taffe J; Rice LJ; Horstead SK; Rogers N; Hodge MA; Guastella AJ
    Am J Med Genet A; 2014 Sep; 164A(9):2232-9. PubMed ID: 24980612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination.
    Weintraub M; Hasday JD; Mushlin AI; Lockwood DH
    Arch Intern Med; 1984 Jun; 144(6):1143-8. PubMed ID: 6375610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Self-induced cutaneous lesions in Prader-Willi syndrome].
    Plantin P; Milochau P; Broussine L; Blondin G
    Ann Dermatol Venereol; 1997; 124(5):390-2. PubMed ID: 9739896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An overview of the efficacy and safety of fenfluramine and mazindol in the treatment of obesity.
    Stahl KA; Imperiale TF
    Arch Fam Med; 1993 Oct; 2(10):1033-8. PubMed ID: 8111484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term weight control study. IV (weeks 156 to 190). The second double-blind phase.
    Weintraub M; Sundaresan PR; Schuster B; Averbuch M; Stein EC; Cox C; Byrne L
    Clin Pharmacol Ther; 1992 May; 51(5):608-14. PubMed ID: 1587075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychopharmacogenetic aspects of Prader-Willi syndrome.
    Tu JB; Hartridge C; Izawa J
    J Am Acad Child Adolesc Psychiatry; 1992 Nov; 31(6):1137-40. PubMed ID: 1429418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open-label pilot study of N-acetylcysteine for skin-picking in Prader-Willi syndrome.
    Miller JL; Angulo M
    Am J Med Genet A; 2014 Feb; 164A(2):421-4. PubMed ID: 24311388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine.
    Hensrud DD; Connolly HM; Grogan M; Miller FA; Bailey KR; Jensen MD
    Mayo Clin Proc; 1999 Dec; 74(12):1191-7. PubMed ID: 10593346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naltrexone and fluoxetine in Prader-Willi syndrome.
    Benjamin E; Buot-Smith T
    J Am Acad Child Adolesc Psychiatry; 1993 Jul; 32(4):870-3. PubMed ID: 8340312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Untoward effects of fenfluramine in autistic children.
    Realmuto GM; Jensen J; Klykylo W; Piggott L; Stubbs G; Yuwiler A; Geller E; Freeman BJ; Ritvo E
    J Clin Psychopharmacol; 1986 Dec; 6(6):350-5. PubMed ID: 3543069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.